399,150 Shares in Drugs Made In America Acquisition II Corp. $DMII Acquired by Wealthspring Capital LLC

Wealthspring Capital LLC purchased a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 399,150 shares of the company’s stock, valued at approximately $4,063,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SkyView Investment Advisors LLC purchased a new stake in shares of Drugs Made In America Acquisition II in the 2nd quarter worth about $2,515,000. Rivernorth Capital Management LLC purchased a new position in Drugs Made In America Acquisition II during the 1st quarter valued at about $2,991,000. Sona Asset Management US LLC lifted its position in Drugs Made In America Acquisition II by 66.7% during the 1st quarter. Sona Asset Management US LLC now owns 500,000 shares of the company’s stock valued at $4,985,000 after acquiring an additional 200,000 shares during the period. Kryger Capital LLC purchased a new position in Drugs Made In America Acquisition II during the 1st quarter valued at about $3,088,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Drugs Made In America Acquisition II during the first quarter worth about $19,960,000.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DMII. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II to a “hold” rating in a report on Saturday, October 24th. Weiss Ratings raised shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, Drugs Made In America Acquisition II currently has an average rating of “Sell”.

Drugs Made In America Acquisition II Stock Up 0.0%

DMII stock opened at $10.21 on Monday. The stock’s 50 day simple moving average is $10.18 and its 200 day simple moving average is $10.08. Drugs Made In America Acquisition II Corp. has a 12-month low of $9.86 and a 12-month high of $10.33.

Drugs Made In America Acquisition II (NASDAQ:DMII) last posted its earnings results on Friday, August 14th. The company reported $0.07 EPS for the quarter.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company.

The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.